NEJM: 40% lower risk of treatment failure!

▎WuXi AppTec content team editors Currently, there are about 1.
8 million children and adolescents under the age of 15 living with HIV in the world.
For this group of people, their treatment options are very limited
.

Especially for pediatric patients, if the therapeutic drug has a poor taste and is inconvenient to take, it will greatly reduce the compliance of long-term treatment
.

Results of a global trial called ODYSSEY led by researchers at University College London (UCL) showed that the antiretroviral drug Dulutevir is not only convenient to take (only needs to be taken orally once a day) compared with previous standard therapy.
), and was able to suppress HIV more effectively in children and adolescents (under 18 years) and reduce the probability of treatment failure by about 40%! The results of the study were recently published in the prestigious medical journal The New England Journal of Medicine (NEJM)
.

Professor Diana Gibb, principal investigator of the ODYSSEY trial and one of the senior authors of the paper, said: "This study provides strong evidence for the widespread use of dulutevir in children and adolescents with AIDS worldwide, and also supports the World Health Organization (WHO).
) HIV treatment recommendations provide the latest evidence
.

” Screenshot source: NEJM Dulutevir is an integrase inhibitor that blocks HIV replication by acting on integrase
.

ODYSSEY is an open-label, randomized, non-inferiority trial to compare Dulutevir-based antiretroviral therapy with prior standard therapy in first-line (ODYSSEY A cohort) and second-line (ODYSSEY cohort) in children and adolescents B cohort) role in treatment
.

The study included more than 700 patients from 29 clinical centers in Africa, Europe and Asia
.

Included patients were randomized to receive the dulutevir regimen or standard of care and were followed for at least two years
.

The primary endpoint of the study was the proportion of patients who failed antiviral therapy within 96 weeks
.

The study's main results showed that 14% of patients receiving Dulutevir had treatment failure (detectable levels of the virus in the blood or HIV-related health symptoms) over a 96-week period; The proportion of patients is about 22%
.

In other words, the Dulutevir-based regimen, which is currently widely used in adult treatment, can reduce the probability of treatment failure by about 40% in the young HIV population compared with standard treatment! ▲The proportion of patients with treatment failure in the 48th, 96th and 144th weeks of the study (Image source: Reference [1]) It is worth noting that previous research evidence from AIDS adult patients has shown that Dulutevir-based antiretroviral therapy Viral therapy may be associated with weight gain
.

The current trial included young AIDS patients who weighed more than 14 kg and the vast majority were 6 years and older, but assessed patients who gained more than 1 kg in weight or grew more than 1 cm in 2 years and found that Durrut Wei did not cause abnormal weight gain in these patients
.

Overall, patients in the dulutevir-treated group had an impressive lipid profile and thus a lower risk of long-term cardiovascular disease
.

Dr.
Anna Turkova, lead author of the study, said: "Only about half of young HIV patients worldwide are currently receiving treatment, and those who are not receiving treatment are at high risk for compromised immune systems and worsening health
.

As a daily dose As a one-time antiretroviral drug, Dulutevir not only costs less, but also can be given to infants and young patients through small tablets or dispersed in water, which has a very important role in improving treatment compliance
.

"The paper emphasizes that previous research Evidence shows that Dulutevir has a high genetic barrier to resistance
.

That said, HIV is relatively less likely to develop resistance to it over time
.

The results of the current ODYSSEY trial confirm this again, with significantly lower rates of drug resistance among children or young adults with AIDS receiving Dulutevir-based therapy
.

Related reading The second case in the world: AIDS self-healing is not a special case without drug treatment! Research is expected to bring new treatments "Nature-Medicine": a single drug, suppresses HIV for up to six months, "elite neutralizing antibody" phase 1 trial published NEJM: once every two months, long-acting preventive therapy reduces HIV infection by 66% One step closer to eliminating HIV transmission, preventive medication reduces infection rate by 92%! "The Lancet" sub-issue publishes real-world data of 10,000 people "The Lancet" sub-issue: Eliminating mother-to-child transmission of HIV, the new treatment plan solves this key problem! References [1] Turkova, Anna, et al.
"Dolutegravir as First-or Second-Line Treatment for HIV-1 Infection in Children.
" New England Journal of Medicine 385.
27 (2021): 2531-2543.
Disclaimer: WuXi The content team of Kant focuses on introducing the progress of global biomedical health research
.

This article is for information exchange purposes only, and the views expressed in this article do not represent WuXi AppTec's position, nor do they represent WuXi AppTec's support or opposition to the views expressed in this article
.

This article is also not a treatment plan recommendation
.

For guidance on treatment options, please visit a regular hospital
.